IMNN
HEALTHCAREImunon Inc
Live · NASDAQ · May 9, Close
What's Moving IMNN Today?
No stock-specific AI insight has been generated for IMNN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.71
Fundamentals
Trading
IMNN News
20 articles- IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026Yahoo Finance·May 5, 2026
- Imunon, Inc. Q4 2025 Earnings Call SummaryMoby·Apr 1, 2026
- IMNN: Enrollment in Phase 3 OVATION 3 Trial Remains Ahead of ScheduleYahoo Finance·Apr 1, 2026
- Imunon Inc (IMNN) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial ManagementYahoo Finance·Mar 31, 2026
- IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 StudyYahoo Finance·Mar 31, 2026
- IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian CancerYahoo Finance·Mar 25, 2026
- IMNN: Updated OVATION 2 Data Shows 14.7-Month Improvement in OS Compared to SoCYahoo Finance·Mar 25, 2026
- IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026Yahoo Finance·Mar 24, 2026
- IMNN: Streamlining Operations to Focus on OVATION 3Yahoo Finance·Feb 6, 2026
- IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDYYahoo Finance·Feb 5, 2026
- IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ RulesYahoo Finance·Dec 30, 2025
- IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026Yahoo Finance·Dec 29, 2025
- IMNN: R&D Day Highlights Potential for IMNN-001…Yahoo Finance·Nov 17, 2025
- Imunon Inc (IMNN) Q3 2025 Earnings Call Highlights: Promising Advances in Immunotherapy and ...Yahoo Finance·Nov 13, 2025
- Imunon (IMNN) Q3 2025 Earnings Call TranscriptMotley Fool·Nov 13, 2025
- IMUNON Reports Third Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Nov 13, 2025
- IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian CancerYahoo Finance·Nov 10, 2025
- IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian CancerYahoo Finance·Nov 10, 2025
- IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer TreatmentYahoo Finance·Nov 7, 2025
- IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025Yahoo Finance·Nov 6, 2025
All 20 articles loaded
Price Data
52-Week Range
$2.71
Fundamentals
Trading
About Imunon Inc
Imunon Inc. is a clinical-stage biotechnology firm focused on pioneering immune-mediated therapies aimed at combating cancer and infectious diseases. Utilizing its proprietary INFECT platform, the company is dedicated to enhancing immune responses that facilitate the effective eradication of malignancies. With a robust pipeline of therapeutics in various stages of clinical evaluation and strategic collaborations that bolster its research capabilities, Imunon is well-positioned to drive notable advancements in immunotherapy, ultimately transforming patient care and establishing a competitive foothold in the biopharmaceutical sector.